Amid Wood­ford de­ba­cle, Im­muno­core cuts val­u­a­tion as it se­cures $74M from Gen­er­al At­lantic — re­port

Im­muno­core ap­pears to be the lat­est domi­no to fall around Neil Wood­ford’s de­ba­cle as it so­lic­its new back­ing at a dras­ti­cal­ly low­er val­u­a­tion.

Once a star in the UK biotech scene, Im­muno­core fetched $320 mil­lion to launch a sprawl­ing op­er­a­tion around TCR re­search and its val­u­a­tion had once reached near­ly $1 bil­lion (£800m). But that fig­ure has been slashed to around $621 mil­lion (£500 mil­lion) in its lat­est fi­nanc­ing, the Tele­graph re­port­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER